Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Odkrivanje dednega sindroma von Hippel-Lindau : določanje mutacij v genu VHL
Authors:ID Milatovič, Maša (Author)
ID Prosenc, Uršula (Author)
ID Novaković, Srdjan (Author)
Files:.pdf PDF - Presentation file, download (512,60 KB)
MD5: 92594979FAF097EC8378EAB474A0D27F
PID: 20.500.12556/dirros/f2ebc768-e38a-4645-a63c-82cd1a89c95c
 
Language:Slovenian
Typology:1.03 - Other scientific articles
Organization:Logo OI - Institute of Oncology
Abstract:Na Oddelku za molekularno diagnostiko Onkološkega inštituta Ljubljana smo uvedli testiranje mutacij v tumorskem supresorskem genu von Hippel-Lindau (VHL). Mutacije v tem genu povečajo verjetnost za nastanek rakastih bolezni, povezanih s sindromom »von Hippel-Lindau« (VHL), kakor tudi z nastankom sporadičnega raka ledvic. Testiranje dednih mutacij pri bolnikih s sumom na sindrom VHL omogoča zgodnjo pravilno diagnozo bolezni. Prisotnost mutacije v genu VHL je dovolj za potrditev diagnoze sindroma VHL tudi ob odsotnosti značilnih tumorjev. Za testiranje prisotnosti mutacij v genu VHL uporabljamo metodo neposrednega sekvenciranja in metodo MLPA (ang. multiplex ligation-dependent probe amplification). S sekvenciranjem odkrivamo točkovne mutacije in manjše delecije ter insercije. Z metodo MLPA pa prisotnost večjih delecij in insercij v genu oziroma delecijo celotnega gena. Pravočasno odkrivanje mutacij v genih, povezanih z nastankom raka, je za nosilce mutacij pomembno, saj je dokazana mutacija razlog za prilagojeno klinično spremljanje in/ali preventivne ukrepe pri nosilcih mutacije. Posledično so zaradi tega povečane možnosti za preprečevanje ali zgodnejše odkrivanje raka.
Keywords:genetika, mutacije, genetski testi
Publication status:Published
Publication version:Version of Record
Year of publishing:2012
Number of pages:str. 87-89, 113
Numbering:Letn. 16, št. 2
PID:20.500.12556/DiRROS-8799 New window
UDC:616.13/.14-056
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-29DLBGMZ
COBISS.SI-ID:1423995 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:4263
Downloads:1180
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Detection of the von Hippel-Lindau hereditary cancer syndrome: determination of mutations in the VHL gene
Abstract:The Department of Molecular Diagnostics at the Institute of Oncology Ljubljana has introduced testing of mutations in the von Hippel-Lindau (VHL) suppressor gene. Mutations in this gene increase the probability for the development of cancerous diseases associated with the »von Hippel-Lindau« (VHL) syndrome and also the development of sporadic kidney cancer. Testing of hereditary mutations in patients suspected of having the VHL syndrome enables early and correct diagnosis of the disease. Presence of a mutation in the VHL gene is sufficient to confirm the diagnosis of VHL syndrome also in the absence of typical tumours. It is tested using the direct sequencing method and the MLPA multiplex ligation-dependent probe amplification) method. While sequencing allows us to detect point mutations and small deletions and insertions, the MLPA method is used to detect the presence of large deletions and insertions in the gene or a deletion of the entire gene. Timely detection of mutations in genes associated with the development of cancer is important for the carriers of mutations, as a proven mutation is a reason for an adapted clinical monitoring and/or preventive measures in mutation carriers. This results in increased possibilities for the prevention and early detection of cancer.


Archive

niGradiv

Back